Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — December 2018

Planlagt Fastgjort Låst Flyttet Genmab
1.5k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • E Offline
    E Offline
    E_L
    wrote on sidst redigeret af
    #895

    over ASH we heard ´Importantly, this study did demonstrate that despite the significant improvement with daratumumab in the initial PSF1, it did not impact the response of the patient in the next line of therapy. Therefore, the PSF2 was improved in the daratumumab arm."´

    1 Reply Last reply
    0
    • E Offline
      E Offline
      E_L
      wrote on sidst redigeret af
      #896

      as in this article on Pollux https://www.raredr.com/conferences/ash-2018/nizar-bahlis-md-recaps-followup-trial-showing-combo-therapy-rr-multiple-myeloma-maintains-high-response-rates-

      1 Reply Last reply
      0
      • SolsenS Offline
        SolsenS Offline
        Solsen
        wrote on sidst redigeret af
        #897

        You are right. But why do we still se some uncertainty to that fact.

        1 Reply Last reply
        0
        • BulderB Offline
          BulderB Offline
          Bulder
          wrote on sidst redigeret af
          #898

          As I see it, the problem is that you'll never get valid OS comparison between DRd and Rd as pts in the Rd-arm, when they relapse, naturally will prefer DRd (Pollux) to continue with.

          1 Reply Last reply
          0
          • BulderB Offline
            BulderB Offline
            Bulder
            wrote on sidst redigeret af
            #899

            Or, if they are refractory to R, then DVd.

            1 Reply Last reply
            0
            • E Offline
              E Offline
              E_L
              wrote on sidst redigeret af
              #900

              seems like a bit of a luxury problem…

              1 Reply Last reply
              0
              • SolsenS Offline
                SolsenS Offline
                Solsen
                wrote on sidst redigeret af
                #901

                Yes but still some KOL questions daras use in first line. To me only price is the question. If its no problem then we se $10 bn without question 🙂

                1 Reply Last reply
                0
                • BulderB Offline
                  BulderB Offline
                  Bulder
                  wrote on sidst redigeret af
                  #902

                  There are doctors with the attitude "save the best for later", who for that reason will not use dara frontline. It's still to be seen how many they are.

                  1 Reply Last reply
                  0
                  • P Offline
                    P Offline
                    pauly
                    wrote on sidst redigeret af
                    #903

                    Rimeligt skørt at have den holdning

                    1 Reply Last reply
                    0
                    • E Offline
                      E Offline
                      E_L
                      wrote on sidst redigeret af
                      #904

                      yea, that is a job for the JNJ sales force... We had research showing the importance of best treatment first... they will have to push that…

                      1 Reply Last reply
                      0
                      • SolsenS Offline
                        SolsenS Offline
                        Solsen
                        wrote on sidst redigeret af
                        #905

                        Certainly a job for JNJ. JW seems confident in winning the battle. 50% instant rise in sales 😉

                        1 Reply Last reply
                        0
                        • troldmandenT Offline
                          troldmandenT Offline
                          troldmanden
                          wrote on sidst redigeret af
                          #906

                          Det har aldrig rigtig givet mening forr mig med det her 50% stigning straks der ligger en godkendelse i 1. line. Hvorffor ikke....? Nu har dde talt om forever at der var stolemangle. Det har været en slags "undskyldning" for væksten ikke har været bedre den seneste tid

                          1 Reply Last reply
                          0
                          • troldmandenT Offline
                            troldmandenT Offline
                            troldmanden
                            wrote on sidst redigeret af
                            #907

                            HVIS det er rigtig vil godkendelse i 1. linee jo iikke løse noget. Så er den ved at ramme et platatueu? Altså at det er SC der skal til for reelt at løfte den meget højere

                            1 Reply Last reply
                            0
                            • troldmandenT Offline
                              troldmandenT Offline
                              troldmanden
                              wrote on sidst redigeret af
                              #908

                              Det virker llidt som at blæse og haave mel i munden samme tid

                              1 Reply Last reply
                              0
                              • T Offline
                                T Offline
                                Tandfeen-2
                                wrote on sidst redigeret af
                                #909

                                JW mente vækst stiger med 50%, altså fra 28mio USD pr mdr til 42mio uds= 3,4 mia USD i 2019.... så til årsregnskab guider han 3- 3,5 mia USD.= kurs 1500-2000

                                1 Reply Last reply
                                0
                                • P Offline
                                  P Offline
                                  polle1
                                  wrote on sidst redigeret af
                                  #910

                                  God morgen og god dag 🙂

                                  1 Reply Last reply
                                  0
                                  • S Offline
                                    S Offline
                                    Sukkeralf
                                    wrote on sidst redigeret af
                                    #911

                                    Trolmannden her er hvad Jan sagde om flaskehalsproblemet i Q# CC:

                                    1 Reply Last reply
                                    0
                                    • S Offline
                                      S Offline
                                      Sukkeralf
                                      wrote on sidst redigeret af
                                      #912

                                      The fourth question is on the bottleneck. What we understand is that in some centers, like the bigger medical centers in the U.S., they are using for the third infusion and further the very quick 90-minute infusion rate. Janssen can, of course, not promote for that because it's not in the label. But we understand that only in the largest centers, James, it's being used as we speak, but not in the community health care centers, where actually the majority of the multiple myeloma patients

                                      1 Reply Last reply
                                      0
                                      • S Offline
                                        S Offline
                                        Sukkeralf
                                        wrote on sidst redigeret af
                                        #913

                                        are treated in the United States. So there's a very limited positive impact, I think, of the 90-minute infusion speed -- infusion times in order to actually make more capacity available. But the real -- I think the real big push will come from the subcu formulation, which we anticipate to be available and also can be promoted for in early 202

                                        1 Reply Last reply
                                        0
                                        • S Offline
                                          S Offline
                                          Sukkeralf
                                          wrote on sidst redigeret af
                                          #914

                                          Og split dosing vil formentlig være godkendt i starten af 2019, så det kan afhjælpe situationen lidt.

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger